Skip to Main Content


The Safety of Tulathromycin Administration in Goats
Kevin E. Washburn*, Wesley Bissett*, Virginia Fajt†, Fred Club, Mitzi Libal, Geoffrey Fosgate‡, Katie E. Smyre′, Kathryn L. Cass′ KCasspicture




To determine if administration of tulathromycin to goats, at 10 times the label dose for cattle and swine, resulted in adverse effects

Animals  Sample Population

10 male mixed-breed goats


Tulathromycin, or an equivalent volume of saline, was administered subcutaneously to treatment and control groups, respectively.  Blood, urine, and fecal samples were obtained from both groups prior to and following treatment for hematology, serum chemistry, urinalysis, and fecal floatation.  Goats were observed daily for evidence of adverse effects following treatment.  Clinical parameters assessed included feed intake, injection site swelling, temperature, pulse and respiratory rate.  Seven days following administration of tulathromycin or saline, a complete post-mortem examination was performed.


Although all treated goats experienced periods of transient pain following administration of tulathromycin, laboratory data in addition to clinical observations, indicated no significant differences of clinical relevance between treatment and control goats.  All goats survived to the end of the study period.  No gross lesions were observed in pertinent tissues upon post-mortem examination.   

Conclusions and Clinical Relevance

The results of this study suggest that administration of tulathromycin to goats at ten times the labeled therapeutic dose for cattle and swine results in clinically mild and transient effects.  Pharmacokinetic studies are needed to determine a therapeutic dose for goats.  If in vitro studies of caprine respiratory pathogens display susceptibility to tulathromycin, this drug may be an effective tool in the treatment of caprine respiratory disease.